Pedro Pa Reyes
Research Subjects
Research Interests
Pedro Pa Reyes has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Maite Vallejo
Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico
5 shared publications - Gilberto Vargas-Alarcón
Research Direction, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico
3 shared publications - José Luis Rosales-Encina
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Alcaldia Gustavo A. Madero, Ciudad de México, 07360, Mexico City, Mexico
2 shared publications - Martha A Ballinas-Verdugo
Department of Molecular Biology, Instituto Nacional de Cardiología “Ignacio Chávez”, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, Mexico City, CP 14080, Mexico
2 shared publications - María Elena Soto
Research Direction, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano No. 1. Col. Sección XVI, Mexico City 14080, Mexico
2 shared publications - Minerva Arce-Fonseca
Department of Molecular Biology, National Institute of Cardiology “Ignacio Chávez”, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, Mexico City 14080, Mexico
2 shared publications
Latest Publications
- Open Access
- 11 March 2013
- Published by Springer Nature in Veterinary Research
- Vol. 44 (1) , 15
Specific humoral and cellular immunity induced by Trypanosoma cruzi DNA immunization in a canine model
Chagas disease has a high incidence in Mexico and other Latin American countries. Because one of the most important known methods of prevention is vector control, which has been effective only in certain areas of South America, the development of a vaccine to protect people at risk has been proposed. In this study, we assessed the cellular and humoral immune response generated following immunization with pBCSP and pBCSSP4 plasmids containing the genes encoding a trans-sialidase protein (present in all three forms of T. cruzi) and an amastigote specific glycoprotein, respectively, in a canine model. Thirty-five beagle dogs were divided randomly into 5 groups (n = 7) and were immunized twice intramuscularly with 500 μg of pBCSSP4, pBCSP, pBk-CMV (empty plasmid) or saline solution. Fifteen days after the last immunization the 4 groups were infected intraperitoneally with 500 000 metacyclic trypomastigotes. The fifth group was unimmunized/infected. The parasitaemia in the immunized/infected dogs was for a shorter period (14 vs. 29 days) and the parasite load was lower. The concentration of IgG1 (0.612 ± 0.019 O.D.) and IgG2 (1.167 ± 0.097 O.D.) subclasses was measured (absorbance) 15 days after the last immunization with both recombinant plasmids, the majority of which were IgG2. The treatment of parasites using the serum from dogs immunized with pBCSP and pBCSSP4 plasmids produced 54% (± 11.8) and 68% (± 21.4) complement-mediated lysis, respectively. At 12 h post immunization, an increase in cytokines was not observed; however, vaccination with pBCSSP4 significantly increased the levels of IFN-γ and IL-10 at 9 months post-infection. The recombinant plasmid immunization stimulated the spleen cell proliferation showing a positive stimulatory index above 2.0. In conclusion, immunization using both genes effectively induces a humoral and cellular immune response.
- 11 March 2013
- Published by Springer Nature in Veterinary Research
- Vol. 44 (1) , 15
Open AccessSpecific humoral and cellular immunity induced by Trypanosoma cruzi DNA immunization in a canine model
Chagas disease has a high incidence in Mexico and other Latin American countries. Because one of the most important known methods of prevention is vector control, which has been effective only in certain areas of South America, the development of a vaccine to protect people at risk has been proposed. In this study, we assessed the cellular and humoral immune response generated following immunization with pBCSP and pBCSSP4 plasmids containing the genes encoding a trans-sialidase protein (present in all three forms of T. cruzi) and an amastigote specific glycoprotein, respectively, in a canine model. Thirty-five beagle dogs were divided randomly into 5 groups (n = 7) and were immunized twice intramuscularly with 500 μg of pBCSSP4, pBCSP, pBk-CMV (empty plasmid) or saline solution. Fifteen days after the last immunization the 4 groups were infected intraperitoneally with 500 000 metacyclic trypomastigotes. The fifth group was unimmunized/infected. The parasitaemia in the immunized/infected dogs was for a shorter period (14 vs. 29 days) and the parasite load was lower. The concentration of IgG1 (0.612 ± 0.019 O.D.) and IgG2 (1.167 ± 0.097 O.D.) subclasses was measured (absorbance) 15 days after the last immunization with both recombinant plasmids, the majority of which were IgG2. The treatment of parasites using the serum from dogs immunized with pBCSP and pBCSSP4 plasmids produced 54% (± 11.8) and 68% (± 21.4) complement-mediated lysis, respectively. At 12 h post immunization, an increase in cytokines was not observed; however, vaccination with pBCSSP4 significantly increased the levels of IFN-γ and IL-10 at 9 months post-infection. The recombinant plasmid immunization stimulated the spleen cell proliferation showing a positive stimulatory index above 2.0. In conclusion, immunization using both genes effectively induces a humoral and cellular immune response.
- Open Access
- 13 November 2012
- Published by Springer Nature in Veterinary Research
- Vol. 43 (1) , 79
Plasmid DNA immunization with Trypanosoma cruzi genes induces cardiac and clinical protection against Chagas disease in the canine model
The only existing preventive measure against American trypanosomosis, or Chagas disease, is the control of the transmitting insect, which has only been effective in a few South American regions. Currently, there is no vaccine available to prevent this disease. Here, we present the clinical and cardiac levels of protection induced by expression toTrypanosoma cruzigenes encoding theTcSP andTcSSP4 proteins in the canine model. Physical examination, diagnostic chagasic serology, and serial electrocardiograms were performed before and after immunization, as well as after experimental infection. We found that immunization with recombinant plasmids prevented hyperthermia in the acute phase of experimental infection and produced lymphadenomegaly as an immunological response against the parasite and additionally prevented heart rate elevation (tachycardia) in the acute and/or chronic stages of infection. Immunization withT. cruzigenes encoding theTcSP andTcSSP4 antigens diminished the quality and quantity of the electrocardiographic abnormalities, thereby avoiding progression to more severe developments such as right bundle branch block or ventricular premature complexes in a greater number of dogs.
- 13 November 2012
- Published by Springer Nature in Veterinary Research
- Vol. 43 (1) , 79
Open AccessPlasmid DNA immunization with Trypanosoma cruzi genes induces cardiac and clinical protection against Chagas disease in the canine model
The only existing preventive measure against American trypanosomosis, or Chagas disease, is the control of the transmitting insect, which has only been effective in a few South American regions. Currently, there is no vaccine available to prevent this disease. Here, we present the clinical and cardiac levels of protection induced by expression toTrypanosoma cruzigenes encoding theTcSP andTcSSP4 proteins in the canine model. Physical examination, diagnostic chagasic serology, and serial electrocardiograms were performed before and after immunization, as well as after experimental infection. We found that immunization with recombinant plasmids prevented hyperthermia in the acute phase of experimental infection and produced lymphadenomegaly as an immunological response against the parasite and additionally prevented heart rate elevation (tachycardia) in the acute and/or chronic stages of infection. Immunization withT. cruzigenes encoding theTcSP andTcSSP4 antigens diminished the quality and quantity of the electrocardiographic abnormalities, thereby avoiding progression to more severe developments such as right bundle branch block or ventricular premature complexes in a greater number of dogs.
- Open Access
- 20 August 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 194
Detection of IS6110 and HupB gene sequences of Mycobacterium tuberculosis and bovisin the aortic tissue of patients with Takayasu’s arteritis
Background: Takayasu’s arteritis (TA) is a chronic inflammatory disease affecting the large arteries and their branches; its etiology is still unknown. In individuals suffering from TA, arterial inflammation progresses to stenosis and/or occlusion, leading to organ damage and affecting survival. Relation of TA with Mycobacterium tuberculosis has been known, but there have been only a few systematic studies focusing on this association. The IS6110 sequence identifies the Mycobacterium tuberculosis complex and the HupB establishes the differences between M. tuberculosis and M. bovis. Our objective was to search the presence of IS6110 and HupB genes in aorta of patients with TA. Methods: We analyzed aorta tissues embedded in paraffin from 5760 autopsies obtained from our institution, we divided the selected samples as cases and controls; Cases: aortic tissues of individuals with Takayasu’s arteritis. Control positive: aortic tissues (with tuberculosis disease confirmed) and control negative with other disease aortic (atherosclerosis). Results: Of 181 selected aorta tissues, 119 fulfilled the corresponding criteria for TA, TB or atherosclerosis. Thus 33 corresponded to TA, 33 to tuberculosis (TB) and 53 to atherosclerosis. The mean age was 22 ± 13, 41 ± 19, and 57 ± 10, respectively. IS6110 and HupB sequences were detected in 70% of TA tissues, 82% in tuberculosis, and in 32% with atherosclerosis. Important statistical differences between groups with TA, tuberculosis versus atherosclerosis (p = 0.004 and 0.0001, respectively) were found. Conclusion: We identified a higher frequency of IS6110 and HupB genes in aortic tissues of TA patients. This data suggests that arterial damage could occur due to previous infection with M. tuberculosis.
- 20 August 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 194
Open AccessDetection of IS6110 and HupB gene sequences of Mycobacterium tuberculosis and bovisin the aortic tissue of patients with Takayasu’s arteritis
Background: Takayasu’s arteritis (TA) is a chronic inflammatory disease affecting the large arteries and their branches; its etiology is still unknown. In individuals suffering from TA, arterial inflammation progresses to stenosis and/or occlusion, leading to organ damage and affecting survival. Relation of TA with Mycobacterium tuberculosis has been known, but there have been only a few systematic studies focusing on this association. The IS6110 sequence identifies the Mycobacterium tuberculosis complex and the HupB establishes the differences between M. tuberculosis and M. bovis. Our objective was to search the presence of IS6110 and HupB genes in aorta of patients with TA. Methods: We analyzed aorta tissues embedded in paraffin from 5760 autopsies obtained from our institution, we divided the selected samples as cases and controls; Cases: aortic tissues of individuals with Takayasu’s arteritis. Control positive: aortic tissues (with tuberculosis disease confirmed) and control negative with other disease aortic (atherosclerosis). Results: Of 181 selected aorta tissues, 119 fulfilled the corresponding criteria for TA, TB or atherosclerosis. Thus 33 corresponded to TA, 33 to tuberculosis (TB) and 53 to atherosclerosis. The mean age was 22 ± 13, 41 ± 19, and 57 ± 10, respectively. IS6110 and HupB sequences were detected in 70% of TA tissues, 82% in tuberculosis, and in 32% with atherosclerosis. Important statistical differences between groups with TA, tuberculosis versus atherosclerosis (p = 0.004 and 0.0001, respectively) were found. Conclusion: We identified a higher frequency of IS6110 and HupB genes in aortic tissues of TA patients. This data suggests that arterial damage could occur due to previous infection with M. tuberculosis.
- 21 July 2008
- Published by Wiley in Cell Biochemistry and Function
- Vol. 26 (7) , 820-823
Comparative study of the residues 63 and 67 on the HLA‐B molecule in patients with Takayasu's arteritis and tuberculosis
Takayasu's arteritis (TA) and tuberculosis (TB) have been associated with major histocompatibility complex genes, especially HLA‐B alleles. However, different HLA‐B alleles have been detected in these diseases. The aim of the study was to compare the distribution of the residues 63 and 67 on the HLA‐B molecule in patients with TA and TB in order to establish a genetic relationship between these two diseases. HLA‐B sequences obtained in 30 patients with TB were compared to those previously reported in TA and healthy controls. 8 out of 30 TB patients studied (26.6%) presented at least one allele with glutamic acid at position 63 and serine at position 67. This was observed in 73% of the TA patients (p = 0.0005). Ten TB (10/30 = 33.3%) and two TA patients (2/26 = 7.7%) did not show similarity at the mentioned positions (p = 0.019). This preliminary study suggests a difference in the distribution of the residues 63 and 67 of the HLA‐B alleles in patients with TA and TB. Copyright © 2008 John Wiley & Sons, Ltd.
- 21 July 2008
- Published by Wiley in Cell Biochemistry and Function
- Vol. 26 (7) , 820-823
Comparative study of the residues 63 and 67 on the HLA‐B molecule in patients with Takayasu's arteritis and tuberculosis
Takayasu's arteritis (TA) and tuberculosis (TB) have been associated with major histocompatibility complex genes, especially HLA‐B alleles. However, different HLA‐B alleles have been detected in these diseases. The aim of the study was to compare the distribution of the residues 63 and 67 on the HLA‐B molecule in patients with TA and TB in order to establish a genetic relationship between these two diseases. HLA‐B sequences obtained in 30 patients with TB were compared to those previously reported in TA and healthy controls. 8 out of 30 TB patients studied (26.6%) presented at least one allele with glutamic acid at position 63 and serine at position 67. This was observed in 73% of the TA patients (p = 0.0005). Ten TB (10/30 = 33.3%) and two TA patients (2/26 = 7.7%) did not show similarity at the mentioned positions (p = 0.019). This preliminary study suggests a difference in the distribution of the residues 63 and 67 of the HLA‐B alleles in patients with TA and TB. Copyright © 2008 John Wiley & Sons, Ltd.
- 10 November 2006
- Vol. 76 (3) , 269-76
[Chronic Chagasic Cardiomyopathy at the Hospital General de Zona no. 24 IMSS. Poza Rica, Veracruz].
Northern Veracruz has conditions, biotic and abiotic, to support Triatomine bugs and vectorial transmission of Trypanosoma cruzi to human beings. Therefore we explore seroprevalence of antibodies to this parasite and the presence of Chronic Chagasic Cardiopathy (CCC) at Cardiology ward in a General Hospital serving North of Veracruz State, and neighbord states Hidalgo, Puebla San Luis Potosi and Tamaulipas. We search for consecutive adult patients attending outpatient and beds assigned to Cardiology between March through September, 2003. An epidemiology questionnaire, clinical work up, chest roentgenogram, 12 lead peripheral EKG and transthoracic echocardiogram were performed in 240 female/males patients. All of them were bled to blindly search for T. cruzi antibodies. Seroprevalence was 8%, 49 cases of dilated cardiomyopathy were diagnosed 23 attributed to chronic diseases such as systemic hypertension diabetes mellitus or ischemic heart disease 12 with idiopathic disease and 14 (29%) had CCC. The latter accumulated epidemiologic features suggestive of vectorial infection. Four additional individuals without CCC but having specific antibodies were considered indeterminate Chagasic cases. This case series identify American Trypanosomiasis among 19 people attending a Cardiology Service, and 14 of them had a severe heart disease linked to progressive and fatal course. This observation points out that Chagas disease could be a regional public health problem in Northern Veracruz.
- 10 November 2006
- Vol. 76 (3) , 269-76
[Chronic Chagasic Cardiomyopathy at the Hospital General de Zona no. 24 IMSS. Poza Rica, Veracruz].
Northern Veracruz has conditions, biotic and abiotic, to support Triatomine bugs and vectorial transmission of Trypanosoma cruzi to human beings. Therefore we explore seroprevalence of antibodies to this parasite and the presence of Chronic Chagasic Cardiopathy (CCC) at Cardiology ward in a General Hospital serving North of Veracruz State, and neighbord states Hidalgo, Puebla San Luis Potosi and Tamaulipas. We search for consecutive adult patients attending outpatient and beds assigned to Cardiology between March through September, 2003. An epidemiology questionnaire, clinical work up, chest roentgenogram, 12 lead peripheral EKG and transthoracic echocardiogram were performed in 240 female/males patients. All of them were bled to blindly search for T. cruzi antibodies. Seroprevalence was 8%, 49 cases of dilated cardiomyopathy were diagnosed 23 attributed to chronic diseases such as systemic hypertension diabetes mellitus or ischemic heart disease 12 with idiopathic disease and 14 (29%) had CCC. The latter accumulated epidemiologic features suggestive of vectorial infection. Four additional individuals without CCC but having specific antibodies were considered indeterminate Chagasic cases. This case series identify American Trypanosomiasis among 19 people attending a Cardiology Service, and 14 of them had a severe heart disease linked to progressive and fatal course. This observation points out that Chagas disease could be a regional public health problem in Northern Veracruz.
- 18 October 2005
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 4,p. CD004102
Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection)
People with Chagas disease (American Trypanosomiasis) may develop progressive and potentially lethal heart conditions. Drugs to eliminate the causative parasite, Trypanosoma cruzi, currently in use have limited therapeutic value and are used in early stages of the disease. Extending the use of these drugs to treat symptomatic chronic parasitism with chronic Chagasic cardiopathy (CCC) and progressive dilated cardiomyopathy has been proposed. To update the systematic review which assessed the effects (harms and benefits) of nitrofurans and imidazolic trypanocidal drugs for treating late stage chronic Chagas disease and CCC. The searches from 2008 were re‐run on 31 March 2010 on the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (Issue 1, 2010), MEDLINE (OVID) (1985 to March 2010), EMBASE (OVID) (1985 to March 2010) and LILACS (1985 to March 2010). The searches of BIREME (1985‐2004), ARTEMISA (1985‐2004) and SCIELO (1985‐2004) were last run in 2004. Indexing terms in English and Spanish were used. No language restrictions were applied. We included randomized controlled clinical trials (RCTs), single or double blind using trypanocidal drugs versus placebo or no treatment in CCC. All articles retrieved were assessed by two reviewers independently, using a predefined check list to determine if they met the inclusion criteria. Two independent reviewers collected data using a pre‐designed form piloted on three articles before the review process started. Disagreements were resolved by a third reviewer. If the information was unavailable the articles were excluded. We planned a quantitative analysis of reduction of parasite load whether recorded as a categorical variable or the reduction of specific antibody titers. However insufficient data were available for quantitative analysis. We prepared a qualitative description of data identified. The updated searches did not identify any new trials. One ongoing study has been added for later evaluation. Previously only one randomized double blind placebo controlled trial and five uncontrolled or non‐randomized studies which were of some relevance were found. Until now there is insufficient evidence to support the efficacy of nitrofurans or imidazolic drugs as recommended treatment in CCC and chronic T.cruzi infections, specifically if overt heart disease is present. A well designed randomized controlled trial is now ongoing which will clarify the efficacy of these drugs, however, it is necessary to establish if new drugs are suitable for treatment of cardiac patients with CCC. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection) Les personnes atteintes de la maladie de Chagas (Trypanosomiase américaine) peuvent développer des problèmes cardiaques progressifs et potentiellement mortels. Les médicaments actuellement utilisés pour éliminer le parasite en cause, Trypanosoma cruzi, ont une valeur thérapeutique limitée et sont administrés dans les phases précoces de la maladie. Il a été proposé d’étendre l’utilisation de ces médicaments afin de traiter l’infection au stade chronique symptomatique associé à une cardiopathie chagasique chronique (CCC) et à une cardiomyopathie dilatée progressive. Mettre à jour la revue systématique qui a évalué les effets (préjudices et bénéfices) des nitrofuranes et des médicaments trypanocides imidazolés pour le traitement de la maladie de Chagas chronique en phase terminale et de la CCC. Les recherches menées depuis 2008 ont été reprises le 31 mars 2010 dans le registre Cochrane des essais contrôlés (CENTRAL) de The Cochrane Library (numéro 1, 2010), MEDLINE (OVID) (1985 à mars 2010), EMBASE (OVID) (1985 à mars 2010) et LILACS (1985 à mars 2010). Les dernières recherches effectuées dans BIREME (1985‐2004), ARTEMISA (1985‐2004) et SCIELO (1985‐2004) datent de 2004. Des termes d’indexation en anglais et en espagnol ont été utilisés. Aucune restriction de langue n'a été appliquée. Nous avons inclus des essais cliniques contrôlés randomisés (ECR) menés en simple ou en double aveugle et comparant des médicaments trypanocides au placebo ou à l’absence de traitement en cas de CCC. Tous les articles récupérés ont été évalués par deux évaluateurs de manière indépendante selon une liste de vérification prédéfinie afin de déterminer s’ils répondaient aux critères d’inclusion. Deux évaluateurs indépendants ont recueilli les données à l’aide d’un formulaire préconçu expérimenté sur trois articles avant de réaliser la revue. Les désaccords ont été résolus par l’intervention d’un troisième évaluateur. Si les informations étaient indisponibles, les articles ont été exclus. Nous avons prévu une analyse quantitative de la réduction de la charge parasitaire, si elle est enregistrée comme variable catégorielle, ou de la réduction des titres d’anticorps spécifiques. Cependant, les données disponibles en quantité insuffisante n’ont pas permis d’effectuer une analyse quantitative. Nous avons préparé une description qualitative des données identifiées. Les recherches mises à jour n’ont identifié aucun nouvel essai. Une étude en cours a été ajoutée pour évaluation ultérieure. Précédemment, un seul essai randomisé en double aveugle contrôlé versus placebo et cinq études non contrôlées ou non randomisées ayant une certaine pertinence ont été trouvés. Jusqu’à présent, les preuves sont insuffisantes pour étayer l’efficacité des nitrofuranes ou des médicaments imidazolés en tant que traitement recommandé de la CCC et des infections à T.cruzi chroniques, plus spécifiquement si une cardiopathie manifeste est présente. Un essai contrôlé randomisé bien conçu est actuellement en cours afin de clarifier l’efficacité de ces médicaments, toutefois il est nécessaire de déterminer si les nouveaux médicaments conviennent au traitement des patients cardiaques souffrant de CCC.
- 18 October 2005
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 4,p. CD004102
Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection)
People with Chagas disease (American Trypanosomiasis) may develop progressive and potentially lethal heart conditions. Drugs to eliminate the causative parasite, Trypanosoma cruzi, currently in use have limited therapeutic value and are used in early stages of the disease. Extending the use of these drugs to treat symptomatic chronic parasitism with chronic Chagasic cardiopathy (CCC) and progressive dilated cardiomyopathy has been proposed. To update the systematic review which assessed the effects (harms and benefits) of nitrofurans and imidazolic trypanocidal drugs for treating late stage chronic Chagas disease and CCC. The searches from 2008 were re‐run on 31 March 2010 on the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (Issue 1, 2010), MEDLINE (OVID) (1985 to March 2010), EMBASE (OVID) (1985 to March 2010) and LILACS (1985 to March 2010). The searches of BIREME (1985‐2004), ARTEMISA (1985‐2004) and SCIELO (1985‐2004) were last run in 2004. Indexing terms in English and Spanish were used. No language restrictions were applied. We included randomized controlled clinical trials (RCTs), single or double blind using trypanocidal drugs versus placebo or no treatment in CCC. All articles retrieved were assessed by two reviewers independently, using a predefined check list to determine if they met the inclusion criteria. Two independent reviewers collected data using a pre‐designed form piloted on three articles before the review process started. Disagreements were resolved by a third reviewer. If the information was unavailable the articles were excluded. We planned a quantitative analysis of reduction of parasite load whether recorded as a categorical variable or the reduction of specific antibody titers. However insufficient data were available for quantitative analysis. We prepared a qualitative description of data identified. The updated searches did not identify any new trials. One ongoing study has been added for later evaluation. Previously only one randomized double blind placebo controlled trial and five uncontrolled or non‐randomized studies which were of some relevance were found. Until now there is insufficient evidence to support the efficacy of nitrofurans or imidazolic drugs as recommended treatment in CCC and chronic T.cruzi infections, specifically if overt heart disease is present. A well designed randomized controlled trial is now ongoing which will clarify the efficacy of these drugs, however, it is necessary to establish if new drugs are suitable for treatment of cardiac patients with CCC. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection) Les personnes atteintes de la maladie de Chagas (Trypanosomiase américaine) peuvent développer des problèmes cardiaques progressifs et potentiellement mortels. Les médicaments actuellement utilisés pour éliminer le parasite en cause, Trypanosoma cruzi, ont une valeur thérapeutique limitée et sont administrés dans les phases précoces de la maladie. Il a été proposé d’étendre l’utilisation de ces médicaments afin de traiter l’infection au stade chronique symptomatique associé à une cardiopathie chagasique chronique (CCC) et à une cardiomyopathie dilatée progressive. Mettre à jour la revue systématique qui a évalué les effets (préjudices et bénéfices) des nitrofuranes et des médicaments trypanocides imidazolés pour le traitement de la maladie de Chagas chronique en phase terminale et de la CCC. Les recherches menées depuis 2008 ont été reprises le 31 mars 2010 dans le registre Cochrane des essais contrôlés (CENTRAL) de The Cochrane Library (numéro 1, 2010), MEDLINE (OVID) (1985 à mars 2010), EMBASE (OVID) (1985 à mars 2010) et LILACS (1985 à mars 2010). Les dernières recherches effectuées dans BIREME (1985‐2004), ARTEMISA (1985‐2004) et SCIELO (1985‐2004) datent de 2004. Des termes d’indexation en anglais et en espagnol ont été utilisés. Aucune restriction de langue n'a été appliquée. Nous avons inclus des essais cliniques contrôlés randomisés (ECR) menés en simple ou en double aveugle et comparant des médicaments trypanocides au placebo ou à l’absence de traitement en cas de CCC. Tous les articles récupérés ont été évalués par deux évaluateurs de manière indépendante selon une liste de vérification prédéfinie afin de déterminer s’ils répondaient aux critères d’inclusion. Deux évaluateurs indépendants ont recueilli les données à l’aide d’un formulaire préconçu expérimenté sur trois articles avant de réaliser la revue. Les désaccords ont été résolus par l’intervention d’un troisième évaluateur. Si les informations étaient indisponibles, les articles ont été exclus. Nous avons prévu une analyse quantitative de la réduction de la charge parasitaire, si elle est enregistrée comme variable catégorielle, ou de la réduction des titres d’anticorps spécifiques. Cependant, les données disponibles en quantité insuffisante n’ont pas permis d’effectuer une analyse quantitative. Nous avons préparé une description qualitative des données identifiées. Les recherches mises à jour n’ont identifié aucun nouvel essai. Une étude en cours a été ajoutée pour évaluation ultérieure. Précédemment, un seul essai randomisé en double aveugle contrôlé versus placebo et cinq études non contrôlées ou non randomisées ayant une certaine pertinence ont été trouvés. Jusqu’à présent, les preuves sont insuffisantes pour étayer l’efficacité des nitrofuranes ou des médicaments imidazolés en tant que traitement recommandé de la CCC et des infections à T.cruzi chroniques, plus spécifiquement si une cardiopathie manifeste est présente. Un essai contrôlé randomisé bien conçu est actuellement en cours afin de clarifier l’efficacité de ces médicaments, toutefois il est nécessaire de déterminer si les nouveaux médicaments conviennent au traitement des patients cardiaques souffrant de CCC.
- 17 September 2003
- Vol. 45 (4) , 243-4
Are imidazolic drugs effective in the treatment of chronic Chagas cardiomyopathy?
- 17 September 2003
- Vol. 45 (4) , 243-4
Are imidazolic drugs effective in the treatment of chronic Chagas cardiomyopathy?
- 5 August 2003
- Vol. 73 (2) , 95-7
[ Systemic and cardiac B Fibrillosis (" Amyloidosis"). A clinical comment].
- 5 August 2003
- Vol. 73 (2) , 95-7
[ Systemic and cardiac B Fibrillosis (" Amyloidosis"). A clinical comment].
- 20 January 2003
- Published by Wiley
- No. 1
Trypanocidal drugs for late stage, symptomatic Trypanosoma cruzi infection (Chagas disease)
- 20 January 2003
- Published by Wiley
- No. 1
Trypanocidal drugs for late stage, symptomatic Trypanosoma cruzi infection (Chagas disease)
- 1 August 2002
- Vol. 72 (2) , 129-37
[How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital].
To estimate health care costs of patients with chronic Chagasic cardiomyopathy (CCC) in a cardiovascular referral center (Instituto Nacional de Cardiología I. Chávez). In a retrospective study, 13 clinical charts of CCC patients treated in the hospital during 1998 were reviewed. Diagnostic and therapeutic procedures and patients admission were identify as well as health care costs, which were drawn from the hospital costs system. 62% of the cases were admitted to the hospital through the out-patient facilities. All the patients had a health care subsidy of 15 to 55% allocated to the institutional budget. Health care costs were calculated for minimal, average, and maximum scenarios, according to the patient's clinical stage and the price of medical equipment used (low, medium, and high). Most of the health care costs are due to the use of high cost diagnostic equipment (33 a 58%) and hospital stay (including the emergency room) (19 a 28%). This is the first approximation to the economic study of Chagas disease in Mexico, providing foundations for further studies on health economics and quality care of CCC, and suggests that prevention should be enhanced.
- 1 August 2002
- Vol. 72 (2) , 129-37
[How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital].
To estimate health care costs of patients with chronic Chagasic cardiomyopathy (CCC) in a cardiovascular referral center (Instituto Nacional de Cardiología I. Chávez). In a retrospective study, 13 clinical charts of CCC patients treated in the hospital during 1998 were reviewed. Diagnostic and therapeutic procedures and patients admission were identify as well as health care costs, which were drawn from the hospital costs system. 62% of the cases were admitted to the hospital through the out-patient facilities. All the patients had a health care subsidy of 15 to 55% allocated to the institutional budget. Health care costs were calculated for minimal, average, and maximum scenarios, according to the patient's clinical stage and the price of medical equipment used (low, medium, and high). Most of the health care costs are due to the use of high cost diagnostic equipment (33 a 58%) and hospital stay (including the emergency room) (19 a 28%). This is the first approximation to the economic study of Chagas disease in Mexico, providing foundations for further studies on health economics and quality care of CCC, and suggests that prevention should be enhanced.